about us
soloMER® technology
pipeline
licensing opportunities
our mission
To deliver and commercialise effective therapeutics for improved patient treatment of cancer and inflammatory diseases.
our vision
To improve the outcomes and quality of life for people combating disease now, and in the future.
our values
Development of therapeutics for patient benefit. Strong science to deliver effective therapeutics.
Individual challenge for collective success. Strength through diversity.
leading the way with soloMER® technology
soloMERs® are small (approximately 11 kDa) and stable proteins that have squeezed a fourth binding loop into their single domain format and crucially are derived evolutionarily from a non-antibody lineage, placing them outside the complex/competitive antibody patent landscape.
soloMERs® are superior to, and differentiated from more traditional antibody platforms as they are pre-disposed to bind cryptic, more occluded epitopes such as recessed active site pockets and grooves in protein targets.
license our patented inventions and proprietary products
Elasmogen has succeeded in isolating high affinity, highly selective and differentiated, patent protected soloMERs® against a number of different target classes demonstrating the power of our platforms. We are actively looking for potential partners who would like to license our products and/or gain access to our proprietary technology platforms for de novo selection campaigns.
On 13th of November, as part of the Excelerate program, advanced higher biology students from Harlaw Academy visited Elasmogen. The students participated in interactive...
Insider.co.uk has announced today the shortlist for the Deal & Dealmakers Awards. Elasmogen is nominated for Early Stage Deal of the Year in partnership with RBC...
On 10th of May Elasmogen team took part in the regional event hosted by the BIA in collaboration with opportunity North East. The event took place at the new BioHub....
Elasmogen Ltd has announced the appointment of Jane Dancer as the Chair of the Board. Jane joined Elasmogen as a non-executive director in April 2022 on the back of new...
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced a global license agreement that gives Elasmogen...
Aberdeen, Scotland, 18 May 2022: Elasmogen – a biopharmaceutical company discovering and developing new therapeutics using its unique soloMERTM platform – has secured...
MADISON – Small, unique antibody-like proteins known as VNARs derived from the immune systems of sharks can prevent the virus that causes COVID-19, its variants, and...
Expertise in drug discovery and the treatment of life-changing inflammatory diseases has been rewarded with prestigious funding via the UKRI’s Future Leaders Fellowship...
At only one tenth the size of traditional antibodies new VNAR biologics could be used to both treat and protect against SARSCoV-2 infections January 25th 2021:...
New grants across multiple territories cover the use of humanised or de-immunised VNARs for therapeutic applications December 9th 2020: Aberdeen, Scotland: Elasmogen...
New awards for COVID-19 and oncology programs support re-opening of labs in Aberdeen Aberdeen, UK, 8th July 2020: Aberdeen drug discovery pioneer, Elasmogen Ltd has...
Intract Pharma Limited London, UK (“Intract”), and Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) have announced an agreement to collaborate and develop novel...
29th April 2020; Elasmogen Limited, Aberdeen, Scotland (“Elasmogen”) are to collaborate with the University of Aberdeen as a partner on a Scottish Government research...
Elasmogen has been featured in BBSRC's report highlighting a few spinout companies that exemplify BBSRC investments in research.
Elasmogen has been nominated for a Life Science Award with Almac Discovery in the Innovative Collaboration category. The finalists in the Innovative Collaboration...
Funding from Deepbridge Capital will support development of next generation biologics January 10th 2020: Aberdeen, Scotland: Elasmogen Ltd, the biopharmaceutical...
We are delighted that The Times has featured Elasmogen in an article titled 'Ruthless killers? Shark antibodies are latest weapon in fight against cancer'.
Elasmogen's CEO, Caroline Barelle is featured in Converge's podcast where she discusses her business journey.
CIOLook, is currently running a special edition on most prominent women leaders and Elasmogen's CEO, Caroline Barelle has given an interview giving her perspective on...
Elasmogen's CEO Dr Caroline Barelle has been featured in Insight Success special edition Successful Women Making a Difference in Biotech. The article can be read here....
Biotech media outlet Labiotech.eu which covers the European Biotech industry, has today, 21 May 2019, listed Elasmogen CEO, Dr Caroline Barelle among top 20 women in...
Elasmogen is delighted to announce that shortlisted finalists for the 2019 BBSRC Innovator of the Year award include our CEO, Dr Caroline Barelle. The BBSRC Innovator...
Craigavon, N.I., UK, 20 Mar 2019 – Almac Discovery, a biopharmaceutical company focused on discovering and identifying innovative therapeutics for the treatment of...
Life Sciences Scotland have interviewed Elasmogen's CEO Caroline Barelle as part of their Insight series. The article can be accessed here.
Novel soloMER based albumin binder will be used for two therapeutic fusion proteins™ Aberdeen, Scotland and Seoul, Korea; January 7th 2019: Elasmogen Ltd, developer of...
Lille, 5 December 2018 - Elasmogen wins another prestigious award during the 7th Edition of BioFIT. BioFIT is one of Europe's leading business...
Elasmogen’s CEO Dr Caroline Barelle won the Academic Entrepreneur of the Year award at Entrepreneurial Scotland's Summit Awards ceremony which took place on 22nd...
Dr. Caroline Barelle, CEO of Elasmogen, is shortlisted as one of 3 finalists in the Academic to Entrepreneur of the Year category. This category recognises an...
Our CEO Caroline Barelle was interviewed by Scottish Business News Network. In her interview, Caroline discusses the journey of starting up Elasmogen and provides an...
£2M joint program receives grant to support research into next generation technology Craigavon, N.I., UK, 6 Aug 2018 – Almac Discovery, a biopharmaceutical company...
17th May 2018: Aberdeen, Scotland: Elasmogen Ltd, developer of soloMERTM biologics, today announced that Dr Caroline Barelle was named as the winner in the “Rising...
Dr. Caroline Barelle (CEO) has been selected as a finalist for the Rising Stars: Extraordinary Talent Award. Some of Scotland’s most dynamic life sciences companies and...
Elasmogen’s CEO Dr Caroline Barelle has been named in Labiotech.eu’s list of top female entrepreneurs. Read the article here.
Combined Feldan Shuttle and Elasmogen soloMER technology will be used to deliver intracellular candidates for two targets Aberdeen, Scotland and Quebec City,...
Funding from Deepbridge Capital, Innovate UK and Scottish Investment Bank will support development of next generation Ophthalmology biologics Thursday, 16 March 2017:...
BBSRC support for research and commercialisation contributed to the creation of award-winning spin-out company Elasmogen by Dr Caroline Barelle and Professor Andrew...
Aberdeen, UK – [July 2016] OBN announced recently the finalists of its 8th Annual Awards covering Biotech, Medtech, Synthetic Biology and Digital Health. The OBN Awards...
Aberdeen, UK – [27th March 2016] As Europe's leading biopartnering and investment conference, BioTrinity brings together investors, pharmaceutical executives and...
